医药生物行业报告：政策加快中药工业结构优化和转型升级，支持中药工业龙头企业发展

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15] - The implementation plan for the high-quality development of the TCM industry (2026-2030) aims to establish a collaborative development system for the entire industry chain by 2030, fostering leading TCM enterprises and promoting the approval of innovative TCM drugs [4][15] - The report identifies specific companies that are expected to benefit from these policies, including Yiling Pharmaceutical, Tianshili, Kangyuan Pharmaceutical, and Fangsheng Pharmaceutical [5][16][17] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of February 2 to February 6, 2026, the A-share pharmaceutical and biotechnology sector rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 3.43 percentage points [6][18] - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline of 2.42% [18] Investment Recommendations 1. Innovative Drugs: The innovative drug sector is expected to continue to be a strong growth area, with a focus on companies with high certainty and relatively low business development (BD) expectation disturbances, such as Innovent Biologics, Sanofi, and others [7][21] 2. Medical Devices: The medical device sector is showing signs of recovery, with leading companies improving their performance in Q3. The report suggests that the pressure from centralized procurement is diminishing, which may lead to valuation recovery [8][23] 3. Traditional Chinese Medicine: The report is optimistic about TCM companies benefiting from centralized procurement and basic drug policies, with specific companies highlighted for their potential growth [29][30] 4. AI in Healthcare: Companies leveraging AI technology in drug development and medical services are expected to see significant benefits, with specific companies listed for each AI application area [9][32][34]